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The use of advanced imaging technology in sport – international cricket is a 
good example – has eliminated some old uncertainties but also uncovered 
new ones that were previously unknown. For example, is it possible for a ball 
to strike a bat without creating a hot spot (local heating through friction 
detected by infra-red cameras)? The same issue of unearthing novel 
questions while addressing old ones might be true of the use of imaging 
technology in dementia. In this issue of Brain, Chételat and co-workers 
explore a new question that has emerged from the use of amyloid PET scans 
in the diagnosis of dementia: how to interpret negative scans in patients who 
have a clinical phenotype that seems classical for Alzheimer’s disease 
(Chételat et al., 2016).  
 
The authors assembled 40 cases with negative amyloid PET scans and a pre-
test diagnosis of Alzheimer’s disease from 4 well-established centres (Caen, 
Melbourne, Amsterdam and San Francisco). Twenty-one of these cases had 
a typical amnestic presentation. Comparison groups were constructed from 
amyloid PET-positive typical Alzheimer’s disease cases and healthy 
volunteers confirmed to be amyloid PET-negative. Inevitably, some limitations 
arose from differences in procedures across centres. However, the authors 
developed and implemented a stringent approach to remove as much 
inconsistency as possible. Strengths of this multi-centre design included 
central blinded re-reading of all PET scans and verification of all clinical 
diagnoses by a pre-defined review process, based on site visits by two core 
diagnosticians. The principal advantage of a formalised and effective 
international collaboration was that the authors were able to assemble enough 
cases to shed some light on the nature and natural history of amyloid-
negative cases thought a priori to have Alzheimer’s disease.  
 
One finding of the study, which is not a surprise, is that the presumptive 
diagnosis of Alzheimer’s disease was not particularly resilient to a negative 
amyloid scan. In approximately two-thirds of cases, and all but one (94%) of 
non-amnestic cases, clinicians reviewed the clinical profile and decided that 
another diagnosis was more suitable (including frontotemporal lobar 
degenerations, Lewy body disease and corticobasal degeneration). These 
data suggest that clinicians have great faith in amyloid PET scans. They 
underline, in a different way, the uncertainty of clinical diagnosis. It remains 
unknown whether the post-PET diagnoses were more or less accurate, 
because a final arbiter of diagnosis is missing. What we do know is that 
clinical diagnoses are labile, indicating a latent uncertainty, especially in 
individuals lacking a demonstrable and well-circumscribed amnesia as the 
core of their cognitive deficit.  
 
The most intriguing patients were those in whom no better alternative 
diagnosis could be found after PET, a group that came to be labelled as 
‘amnestic amyloid-negative unchanged’. The authors identified 11 such cases 
and were able to sketch a clinical and radiological picture of this entity. In the 
supplementary material (Table S4) they provide case-by-case descriptions, a 
refreshing variation from a literature that is often rich on imaging detail but 
light on clinical description. As a group, these cases demonstrated subtle 
atrophy and hypometabolism of the posterior cingulate region (Figure 3 of the 
paper), features which are among the earliest changes to emerge in incipient 
Alzheimer’s disease (Nestor et al. 2003, Pengas et al. 2010), but they lacked 
the more widespread neocortical alterations of typical amyloid-positive cases. 
 
The key question, beyond the reach of this study, is what these alterations in 
the posterior cingulate region represent pathologically. One particular 
speculation of Chételat et al. revolves around neuropathological descriptions 
of Alzheimer’s disease cases in which tau-related pathology predominates 
and amyloid plaques are sparse. An interesting recent observation, which 
supports this view, comes from a single case of a patient with a presenilin-1 
mutation, imaged with both amyloid and tau PET tracers (Figure 1, Smith et 
al. 2016). In this case, tau tracer uptake was strongly localised to midline 
posterior regions in a pattern closely matching that of hypometabolism. The 
spatial relationship between amyloid tracer binding and metabolism was less 
consistent. Chételat et al. correctly point out that visualisation of tau could 
provide greater diagnostic certainty. Another detail not to lose sight of is the 
exact binding target of amyloid tracers in the brain. Both Pittsburgh 
Compound B and Florbetapir, as used here, bind predominantly to β-pleated 
sheet structures and are therefore not generic amyloid ligands but rather 
ligands for insoluble amyloid aggregates. One possibility is that amyloid 
‘positive’ and ‘negative’ cases differ in the processing of amyloid downstream 
of soluble oligomers and non-fibrillar forms that are nevertheless neurotoxic 
(leading to what might be viewed as ‘false negatives’). Of the 21 amnestic 
amyloid-negative cases identified prior to PET, 14 were female and 15 did not 
carry an apolipoprotein E4 allele, in contrast to typical amyloid-positive cases. 
Apolipoprotein E4 is known to have an effect on the deposition of fibrillar 
insoluble amyloid (Schmechel et al. 1993) of the sort that is avidly bound by 
amyloid tracers. 
 
One reason that tau or soluble amyloid interpretations are so often put 
forward, and are so intuitively appealing, is that they fit within traditional 
boundaries: they demand no interrogation of our conceptual model of 
Alzheimer’s disease. However, the real answer might not be so orthodox. The 
retrosplenial cortex, which lies within the atrophied and hypometabolic region 
described by Chételat and co-workers, is involved in episodic memory, 
navigation, imagination and planning for the future (Vann et al. 2009). Any 
pathology that affects this region might be expected to produce a clinical 
picture that overlaps with typical amnestic Alzheimer’s disease. Isolated 
vascular lesions of this region are rare but have been associated with an 
amnesic syndrome (Valenstein et al. 1987). The extent of involvement of the 
retrosplenial cortex or its connections in more diffuse vascular disease is not 
known. Furthermore, alterations in this region are found in schizophrenia, 
bipolar disorder, post-traumatic stress disorder and dyslexia. The retrosplenial 
cortex also appears to be particularly sensitive to remote damage. In both 
patients and animal models, lesions of the hippocampus and medial 
diencephalon cause retrosplenial hypoactivity (Vann et al. 2009), which does 
not simply reflect the deafferentation of the retrosplenial cortex. As such, 
retrosplenial dysfunction appears to be a reliable sentinel marker of pathology 
within the hippocampal-thalamic network (Figure 2). It is possible that the 
amyloid-negative group is a collection of diverse mimics of amnestic 
Alzheimer’s disease, connected by the common feature of retrosplenial/ 
posterior cingulate regional dysfunction. The fact that many followed a 
subsequent progressive course implies neurodegenerative disease, rather 
than other types of mimic. However, the authors rightly emphasise the 
heterogeneous natural history of amyloid-negative cases. 
 
Correlation with post mortem diagnosis is an obvious way to shed more light 
on the subgroups, and transitions between diagnostic groups, described by 
Chételat et al. However, it is not the only way forward. Atrophy and 
hypometabolism are relatively blunt measures of structure and function. 
Investigation of cingulate connections and patterns of connectivity would 
deepen our understanding of the alterations in this broad region, particularly 
as it harbours subregions with quite different connectivity profiles (Morris et 
al., 1999; Aggleton et al., 2012). Functional studies are also important. Leech 
and Sharp described, from a synthesis of previous functional studies, how 
subregions relate differentially to the default modes of brain function, salience, 
attention and cognitive control, with a putative role for the posterior cingulate 
cortex in tuning network dynamics (Leech and Sharp 2014). The results of 
Chételat et al. also suggest scope for further neuropsychological investigation. 
 
One challenge that arose during the review of Chételat et al. paper was what 
the ‘amnestic amyloid-negative unchanged’ group should be called – should 
they be called ‘amyloid-negative Alzheimer’s disease’ (a pragmatic use of 
clinical criteria, an oxymoron, or too uncertain to be either)? Diagnostic labels 
have a natural life cycle. In some cases, as the field of knowledge expands, it 
becomes increasingly hard to place the original meaning of a term. Biomarker 
data can add support to a diagnostic label but can also unveil hidden 
contradictions. Imaging has added a dimension to the diagnostic space that 
was not present when many diagnostic labels were coined. We will never 
know the amyloid-PET status of Alois Alzheimer’s cases. Labels eventually 
sink, weighed down by the debate around their precise modern meaning, 
which comes to outweigh the buoyancy of their advantages in classifying the 
diagnostic space. ‘Binswanger’s disease’ is one example of a term that now 
lies on the ocean floor (Hachinski 1991). The implications of PET tracer 
studies for the lexicon surrounding common Alzheimer-like dementias will 
depend on further investigation and the knowledge that ensues. However, any 
hope that amyloid imaging would lead to simple distinctions between 
Alzheimer’s disease and non-Alzheimer dementias looks forlorn: it is not 
inevitable that new techniques will simplify disease nosology. As a modern 
cricketer would now tell you, technology brings new yet limited clarity; we 
should embrace it, but not expect it to end controversy. 
 
  
Figure Legends 
 
Figure 1. Posterior tau tracer binding co-localised with hypometabolism 
in a 38-year-old man with a presenilin-1 mutation.  
Imaging was performed with a tracer for insoluble amyloid (18F-Flumetamol, 
far left column) and a tau tracer (18F-AV-1451, second column). The 
strongest tau tracer binding is seen in posterior midline regions including the 
posterior cingulate cortex. Part of this region corresponds very closely to a 
sharply-defined area of hypometabolism. The implication is that even if 
amyloid were sparse, posterior cingulate hypometabolism would be seen in 
association with tau (Reprinted from Smith et al. Journal of Alzheimer’s 
Disease, with permission from IOP Press. The publication is available at IOP 
Press through http://dx.doi.org/10.3233/JAD-151004). 
 
Figure 2. The retrosplenial cortex as a sentinel for damage elsewhere in 
the hippocampal-thalamic network. 
Reduced expression of the immediate-early gene, c-fos, in the rat 
retrosplenial cortex following a bilateral mammillothalamic tract (MTT) lesion 
(right) compared to a control animal (left). c-fos is considered a marker of 
neuronal activity, so reduced expression would indicate hypofunctionality of 
the retrosplenial cortex. The lesions only indirectly disconnect the retrosplenial 
cortex, so changes in immediate early gene expression are not due simply to 
deafferentation. 
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